Cargando…

Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis

OBJECTIVE: An oral lipid based formulation that exhibits tropical stability (iCo-010) was developed to enhance the absorption of orally administered amphotericin B (AmB). iCo-010 has previously shown high efficacy in an acute model of systemic candidiasis in rats, directing the focus of this study t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibrahim, Fady, Sivak, Olena, Wasan, Ellen K, Bartlett, Karen, Wasan, Kishor M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231414/ https://www.ncbi.nlm.nih.gov/pubmed/24164705 http://dx.doi.org/10.1186/1476-511X-12-158

Ejemplares similares

Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
por: Sivak, Olena, et al.
Publicado: (2011)

A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model
por: Wasan, Ellen K., et al.
Publicado: (2010)

In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines
por: Leon, Carlos G, et al.
Publicado: (2011)

Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections
por: Wasan, Ellen, et al.
Publicado: (2022)

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
por: Cuddihy, Grace, et al.
Publicado: (2019)

Effects of climate change on soil health resulting in an increased global spread of neglected tropical diseases
por: Wasan, John Paul M., et al.
Publicado: (2023)

Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases
por: Leon, Carlos G., et al.
Publicado: (2008)

Protonated nanostructured aluminosilicate (NSAS) reduces plasma cholesterol concentrations and atherosclerotic lesions in Apolipoprotein E deficient mice fed a high cholesterol and high fat diet
por: Sivak, Olena, et al.
Publicado: (2009)

Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia
por: Wang, Xia, et al.
Publicado: (2017)

Analytical Strategies to Analyze the Oxidation Products of Phytosterols, and Formulation-Based Approaches to Reduce Their Generation
por: Gachumi, George, et al.
Publicado: (2021)

Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome
por: Gershkovich, Pavel, et al.
Publicado: (2015)

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery
por: Mohammed, Munawar A., et al.
Publicado: (2017)

Designing Fast-Dissolving Orodispersible Films of Amphotericin B for Oropharyngeal Candidiasis
por: Serrano, Dolores R., et al.
Publicado: (2019)

Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis
por: Sosa, Lilian, et al.
Publicado: (2019)

Amphotericin B lipid formulations and target-site penetration into human body fluids
por: Weiler, Stefan, et al.
Publicado: (2008)

149. Efficacy of Cochleated Amphotericin B (CAMB) in Mouse and Human Mucocutaneous Candidiasis
por: Desai, Jigar V, et al.
Publicado: (2020)

The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
por: Solinas, Cinzia, et al.
Publicado: (2020)

Canadian contributions to research on neglected tropical diseases
por: Gyorkos, Theresa W., et al.
Publicado: (2021)

Data on statistical experimental design to formulate amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis
por: Melo, Carolina M., et al.
Publicado: (2020)

Drug Delivery Technology Development in Canada
por: Wasan, Kishor M., et al.
Publicado: (2019)

Development and characterization of amphotericin B nanoemulsion-loaded mucoadhesive gel for treatment of vulvovaginal candidiasis
por: Patil, Mrunal U., et al.
Publicado: (2022)

ICO investors
por: Fahlenbrach, Rüdiger, et al.
Publicado: (2020)

Development and Characterization of Liposomal Formulations Containing Phytosterols Extracted from Canola Oil Deodorizer Distillate along with Tocopherols as Food Additives
por: Poudel, Asmita, et al.
Publicado: (2019)

Which New Approaches to Tackling Neglected Tropical Diseases Show Promise?
por: Spiegel, Jerry M., et al.
Publicado: (2010)

Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups
por: Campbell, Rebecca S, et al.
Publicado: (2013)

Pharmacokinetics and Drug Metabolism in Canada: The Current Landscape—A Summary of This Indispensable Special Issue
por: Davies, Neal M., et al.
Publicado: (2018)

A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis
por: Benjamin, Daniel K., et al.
Publicado: (2018)

370. Efficacy of Cochleated Amphotericin B (C-AMB) in Mouse Models of Oropharyngeal and Vulvovaginal Candidiasis
por: Desai, Jigar V, et al.
Publicado: (2018)

Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015)

Design of amphotericin B oral formulation for antifungal therapy
por: Liu, Min, et al.
Publicado: (2017)

Colloque ICO '89
por: Moulin, B, et al.
Publicado: (1989)

LBODP010 A Case of Glucocorticoid Resistance Syndrome
por: Sudhakar, Shwetha Mallesara, et al.
Publicado: (2022)

Role of endocytosis and trans‐endocytosis in ICOS costimulator‐induced downmodulation of the ICOS Ligand
por: Aragoneses‐Fenoll, Laura, et al.
Publicado: (2021)

Use of a Long-Acting Opioid Microsphere Formulation to Overcome Difficulties in Swallowing Pain Medication
por: Anderson, Nathan, et al.
Publicado: (2020)

Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis
por: de Bastiani, Fernanda Walt Mendes da Silva, et al.
Publicado: (2020)

Tailoring thixotropic mixed-lipid nanoconstructs of voriconazole for the management of Vulvovaginal candidiasis: Formulation, statistical optimization, in vitro characterization and in vivo assessment
por: Abd-Elsalam, Wessam H., et al.
Publicado: (2021)

P010 Abstract Withdrawn
Publicado: (2021)

Nephrotoxicity of three formulations of amphotericin B: trial sequential analysis
por: Caputo, Rosaria, et al.
Publicado: (2020)

A Comparison of AmBisome(®) to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants
por: Jeon, Ga Won, et al.
Publicado: (2007)

Development of a Topical Amphotericin B and Bursera graveolens Essential Oil-Loaded Gel for the Treatment of Dermal Candidiasis
por: Espinoza, Lupe Carolina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1fjterou49kne3f0496jpqcp2s